Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

find more articles

Khondrion announces publication of qualitative study informing endpoint selection for the KHENERFIN phase 3 trial in m.3243A>G primary mitochondrial disease

Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue

Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease

view all articles